Natera inc NTRA.US 總覽分析
)NTRA 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分中等，已經有部位可以持續持有，若想建立新部位可以等待價值評分轉變為4分以上、股利提升為2分以上
NTRA 近期報酬表現
1.54%
Natera inc
1.31%
同產業平均
0.58%
S&P500
與 NTRA 同產業的標的表現
- SEER Seer inc價值 2 分趨勢 3 分波段 2 分籌碼 1 分股利 1 分查看更多
NTRA 公司資訊
Natera, Inc. provides cell-free DNA (cfDNA) and genetic testing, dedicated to oncology, women's health, and organ health. The Company's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. It has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women's health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.